trial

Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients

NCTId NCT01598623
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Unknown
Enrollment 48 (estimated)
Sponsored by Sheba Medical Center
Primary completion 2014-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Unknown
Enrollment
48 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-05
Primary completion
2014-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OxytocinSocial Skills Training

Sponsors

Sheba Medical CenterLead Sponsor

Investigators

1
Mark Weiser, MDPrincipal Investigator

Sites

1 total
Ramat Gan, Israel

Linked catalysts

1
Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Pa — primary completion2014-02

Facts & assertions

4 sourced
Enrollment
48
Phase
PHASE2
Primary Completion Date
2014-02
Status
UNKNOWN
relationships
The graph out of here
drug
Oxytocin
drug
Social Skills Training
drug
lead_sponsor
Sheba Medical Center
company
indication
Oxytocin + Social Skills Training
indication
Placebo + Social Skills Training
indication
Placebo + Non Specific Counselling
indication
investigator
Mark Weiser, MD
person